Publications by authors named "K Dheda"
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Hum Vaccin Immunother
December 2024
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study's pre-crossover/booster phase were previously reported. This phase 2a/b clinical trial in South Africa (2019nCoV-501/NCT04533399) revisits 1:1 randomly assigned HIV-negative adults (18-84 years) and medically stable PLWH (18-64 years) who previously received two NVX-CoV2373 doses (5 μg recombinant Spike protein with 50 μg Matrix-M™ adjuvant) or placebo.
View Article and Find Full Text PDFArticle Synopsis
- Tuberculous pleural effusion (TPE) is a common form of tuberculosis outside the lungs, but current diagnostic methods like Xpert Ultra are not very effective, with a sensitivity of around 30%.
- A study in South Africa and India tested a new quick diagnostic method called IRISA-TB, comparing it against other assays and examining biopsy samples for TB confirmation.
- Results showed IRISA-TB had significantly better sensitivity (81.8%) and negative predictive value than Xpert Ultra and also outperformed other methods, indicating it could be a more reliable diagnostic tool for TPE.